News What do midterms mean for Trump's pharma and health agenda? As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback.
News Despite US policy changes, drug prices stay stubbornly high US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
Market Access UK’s next pricing and access scheme to last for 7 years Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.
Market Access One year after MFN: How US policy is reshaping the global ph... Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing.
News PhRMA sues Trump administration over GLOBE rebate scheme PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation pricing in Medicare Part B in a US district court.
News GLOBE model finalised, with narrowed scope and fewer savings CMS has finalised a new drug pricing policy for Medicare that has drawn sharp criticism from the pharma industry.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.